Rx Minute: Offsets in Heart Failure Treatment & Seniors Selecting Lower Costs Part D Plans

November 2012

Last month, a study published in the American Journal of Managed Care found a significant association between modest increases in adherence to heart failure (HF) medications and reduced medical spending among Medicare beneficiaries.[1]

Rotary International and Global Partners Contribute to a Polio-Free India

Washington, D.C. (November 3, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) and its members are pleased to celebrate one of the most significant global health achievements of the 21st century.  For over the past three years, we have supported Rotary International’s PolioPlus program in India through grants and contributions, some of which have been matched by the Bill and Melinda Gates Foundation. 

PhRMA Statement on Bloomberg Article

Washington, D.C. (September 19, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today:

PhRMA Statement on Avalere Health Analysis on Medicare Part D Premiums

Washington, D.C. (September 25, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on findings from Avalere Health on Medicare Part D premiums:

Speech: John J. Castellani National Press Club Remarks

Remarks
John J. Castellani
President & CEO
Pharmaceutical Research and Manufacturers of America
The National Press Club
Washington, D.C.
Thursday, September 20, 2012

 

Thank you, Keith for that kind introduction. And my thanks to all of you here for joining me this morning.

Researchers and Patient Advocates Honored with PhRMA Award

Washington, D.C. (September 7, 2012)— The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the recipients of the first annual Research and Hope Awards. This year’s award honors outstanding achievements in academia, the biopharmaceutical research sector, as well as the patient and caregiving communities to help advance medical progress and patient care for Alzheimer’s disease.

PhRMA Statement Regarding Prescription Drug User Fee Act Reauthorization

Washington, D.C. (June 18, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today:

PhRMA Statement Regarding Prescription Drug User Fee Act Reauthorization

Washington, D.C. (May 24, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today:
 

Counterfeit Medicines: Q&A with Pfizer's Chief Security Officer

05.21.12 | By

The editors at The Catalyst recently asked John P. Clark, Vice President and Chief Security Officer, Pfizer Inc., a few questions about being on the front line in the battle against foreign counterfeit medicines. John provided a snapshot of the risks patients could face if the closed U.S. drug supply system were to open up. I urge you take a close look at all the pictures provided by Pfizer Inc.

Speech: 2012 PhRMA Annual Meeting: President's Address

John J. Castellani
President & CEO
Pharmaceutical Research and Manufacturers of America
Annual Meeting Address
Boston, Massachusetts
April 12, 2012

In our industry today, everyone uses familiar words to describe what we do: Innovation, progress, technology, value, science, partnership, solutions, jobs and so many more.

But to resonate, these words must do more than just describe – they must tell our story.

Pages

Subscribe to RSS - Opinion